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tus in four Cocoa clinics of Ghana. Methods: A descriptive cross-
sectional study of diabetes management was carried out in the four
Cocoa clinics of Ghana from January to December 2009. The “cost-of-
illness” approach from the institutional perspective was used. A
pretested data extraction form was used to review the medical records
of 304 randomly selected diabetic patients. Results: The patients’
mean age was 55.4  9.4 years. The mean annual ﬁnancial cost of
managing one diabetic case at the clinics was estimated to be
Ghana cedi (GHS) 540.35 (US $372.65). Service cost constituted 22%
of the cost, whereas direct medical cost constituted 78% of the cost.
Drug cost was 71% of the ﬁnancial cost. The cost of hospitalization
per patient-day at Cocoa clinics was estimated at GHS 32.78 (US
$22.61). The total ﬁnancial cost of diabetes management was
estimated at GHS 420,087.67 (US $289,715.63). This accounted foree front matter Copyright & 2015, International S
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.1016/j.vhri.2015.08.005
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ndence to: Ernest Attuquaye Quaye, Medical Depa8% of the total expenditure for the clinics in the year 2009. The
study showed that facility type, type of diabetes, and presence of
complication are associated with the cost of diabetes management
to Cocoa clinics. Conclusions: The mean age of detection suggests
delay in diagnosis of diabetes mellitus and accompanying compli-
cations, which has cost implications. Policy that enhances early
detection of diabetes in clinical practice would therefore improve
management and reduce costs. The ﬁnancial cost of managing
diabetes can be used to forecast the economic burden of the disease
in the area.
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Diabetes mellitus is one of the most common chronic diseases.
The number of diabetes cases has been increasing worldwide
with a corresponding increase in health care budgets. It has thus
become a growing public health burden for patients, health care
providers, and society [1–4].
Complications resulting from late diagnosis and late presen-
tation, lack of access to essential medication and services, and
poor management of diabetes have created a heavy socioeco-
nomic burden for Africa. Financing health care is one of the
building blocks of health systems [5]. External ﬁnancial assis-
tance is required in the average low-income country to improve
access to quality basic health service. More than 75% of the
health expenditure, however, comes from domestic sources [6].
Financing of public sector service has gone through several
reforms, ranging from out-of-pocket (before independence)
expenses to national health insurance (currently) in Ghana. The
National Health Insurance Scheme is based on District Mutual
Health Insurance Schemes operating in all 145 districts of the
country. The National Health Insurance Scheme covers both theformal and informal sectors of the economy with the goal of
providing universal health coverage for all Ghanaians. The
national coverage as at December 31, 2009, stood at 62% at the
time of this study [7–10].
The beneﬁt package consists of basic health care and covers
about 95% of the diseases in Ghana. Provider payment methods
used by the District Mutual Health Insurance Schemes are the
Diagnosis Related Groups for services only and Itemized Fee for
Service to pay for medicines on the National Health Insurance
Scheme drug list.
Cost-of-illness evaluation of diabetes has been conducted
over the past three decades in many countries [11]. The cost-of-
illness study has been used for different purposes. It provides
estimates of possible health care costs that can be avoided by
institutions and society. It is therefore of interest to economists,
policymakers, and health service researchers. These estimates
have also been used in identifying the burden of disease, possible
areas for future intervention, and establishing priorities in health
care and research [12]. Although there is no standard method of
estimating cost of illness, a novel method has been made the
standard: the direct cost and the indirect cost [13]. The resourcesociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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and treatment of diabetes, are the direct economic costs. The
potential resources that could be lost and represent the impact,
present or future, and the opportunities lost to the individual and
the society as a result of diabetes are the indirect economic costs.
These are not easily measured or calculated and include morbid-
ity, disability, and premature mortality [11].
Cost-of-illness studies have rarely been conducted in Ghana.
According to a report based on Korle Bu Teaching Hospital
statistics and patients’ accounts, the cost of managing one case
of diabetes in Ghana ranged between Ghana cedi (GHS) 167 and
GHS 392 in 2001 to between GHS 1200 and GHS 7200 in 2007 [14].
In Mali, it cost approximately US $21.24 and in Zambia US $52 per
month for diabetes care [15].
Ghana Cocoa Board has a workplace policy of conducting pre-
employment medical examination for its newly employed staff.
The medical examination covers screening for diabetes, hyper-
tension, and other disease conditions through diagnostic services
and physical examination. The dependents of the newly
employed, who are covered by the institution, are, however,
excluded from this pre-employment medical examination. Staff
and their dependents who suffer from diabetes might have been
diagnosed late, probably with complications. Prevention of the
onset of diabetes and efﬁcient treatment protocols will reduce
cost and enhance quality of life. It is also a way to prevent
diabetes from becoming the leading cause of disability and death
[16]. An analysis of the cost of managing diabetes mellitus will
thus serve as the basis for planning and resource allocation by
Cocoa clinics in Ghana and will also provide the evidence needed
for early detection and management of the disease.Methods
Study Site and Population
The government of Ghana, the private sector, traditional non-
governmental organizations, civil society, and community groups
have been involved in the provision of health services in Ghana.
There exist a strong collaboration and partnership with minis-
tries, departments, and agencies whose policies and services
have a major impact on health outcomes. The health services
are organized in several levels from the subdistrict to the national
level and include both clinical and public health services from the
private and public facilities.
Ghana Cocoa Board established the Accra Cocoa clinic in 1972
to provide medical services to its staff and their dependents as
well as cocoa farmers. It established itself as a provider of good
services and was opened to the general public in 2002. There are
four clinics currently located in Accra, Kumasi, Akim-Tafo, and
Tema. The National Health Insurance Authority accreditation
survey in 2006 placed the Accra and Kumasi clinics at the level of
a district hospital, the Akim-Tafo clinic at the level of a polyclinic,
and the Tema clinic at the level of a health center.
All medical records of diabetic cases were conﬁrmed by a
medical doctor. Diabetic cases belong to all age groups and from
both sexes. Patients should have been regular for checkup and
received treatment from January 1, 2009, to December 31, 2009.Study Design
The study design was a descriptive cross-sectional survey of cost
of treatment of diabetic patients. It was a retrospective quanti-
tative study of the average annual treatment costs using the
prevalence-based approach of cost-of-illness study from the
institutional perspective.Data Collection
Data were collected at the four facilities between May and July
2010 using a pretested data extraction form. The extraction form
was coded to correspond to a particular medical record for the
purposes of auditing and data cleaning.
Sample Size Determination
The medical records of 304 diabetic patients from the four clinics
were desk reviewed. This allowed the estimation of patient cost
of diabetes management to the clinics at a prevalence of 3.0%,
worst acceptable power of 0.05, and conﬁdence interval of 95%.
The statcalc function of Epi Info version 3.4.1 (July 2007) was used
in estimating the sample size for each clinic.
Sampling Procedure
All the four Cocoa clinics were purposively selected for conven-
ience. Quota sampling was used to select the number of medical
records to be reviewed from each facility using the outpatient
department (OPD) attendance proportion of diabetic patients,
which varied for each facility. A list of diabetic patients who
attended the facilities in 2009 was generated by the Practice
Manager (version 2, Browse.com) software used at the clinics.
Systematic sampling was then used to select each medical record
for estimating patient cost. The sample interval was determined,
and simple random sampling was used to select the ﬁrst number
in the sample interval.
Cost-of-Illness Analysis
The mean ﬁnancial cost was the sum of the mean service cost
and the mean direct medical cost. The mean service cost was
obtained by estimating the unit service cost per patient per OPD
visit. The records obtained for the year 2009 from the accountant
on expenses made at the cost centers were entered on a spread-
sheet. The expenses were categorized into cost on personnel,
administrative cost, material and supplies cost, and maintenance
cost for each facility. The unit service cost for each facility was
estimated using the total service cost at each facility divided by
the total OPD attendance for each facility. The total service cost
for each diabetic patient was obtained by multiplying the unit
service cost for the facility by the number of OPD visits within the
year 2009 by the diabetic patient. The direct medical cost for each
diabetic patient whose medical record was reviewed was
obtained by summing the laboratory cost, drug cost for diabetes
and diabetes complications, specialist cost for diabetes care,
emergency/ambulance cost related to diabetes services,
diabetes-related hospitalization cost, and surgical cost for dia-
betes complications in the year 2009.
Statistical Analysis
STATA version 10 was used to determine the descriptive statis-
tics of the patients as well as the mean ﬁnancial cost of diabetes
management.
Independent t test was used to analyze association between
sexes, type of diabetes, and number of complications. Analysis of
variance on means was also conducted to analyze the association
between ﬁnancial cost (dependent variable) and some independ-
ent variables such as the age group, type of client, and facility
type.
Sensitivity Analysis
In analyzing the uncertainty of the results, one-way simple
sensitivity analysis was conducted. The pharmaceutical compo-
nent of the mean ﬁnancial cost of diabetes was used because
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estimating the mean ﬁnancial cost of diabetes management
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.Results
The average age of the 304 patients whose medical records were
reviewed was 55.4  9.4 years, which represents about 75% of the
diabetic patients. The minimum age observed was 17 years,
whereas the maximum age was 86 years. The number was made
up of 167 males and 137 females. There were 184 diabetic patients
from Accra, 51 from Akim-Tafo, 45 from Kumasi, and 24 from
Tema facilities.
The total ﬁnancial cost (cost of medical services and medical
supplies) for the four facilities for the year 2009 was approx-
imately GHS 5.3 million (US $3.7 million). The total number of
OPD visits recorded was 249,029, with 776 visits by diabetic
patients. The average unit cost of OPD service (per visit) was
estimated at GHS 14.05 (US $9.69). However, this varied for each
facility (Table 1). Although the total medical service cost for Accra
constituted about 65% of the total cost for all facilities, it had the
lowest unit service cost of GHS 12.02 (US $8.29) per OPD visit
because of the high OPD attendance. The Tema facility, which
recorded the lowest medical service cost of 6.3% of the total, with
a low OPD attendance recorded the highest unit service cost of
GHS 25.59 (US $17.65). Fig. 1.
The mean ﬁnancial cost per diabetic patient per year at the
four facilities was estimated at GHS 540.35 (US $372.65). However,
the mean ﬁnancial cost varied per facility (Table 1). The analysis
of variance between the mean ﬁnancial cost for the facilities
indicated that the facility type was signiﬁcant (P ¼ 0.018) in the
ﬁnancial cost of diabetes management (Table 2).
The mean service cost constituted 22% and the direct medical
cost constituted 78% of the mean ﬁnancial cost. Drug cost was
71% of the ﬁnancial cost, representing the highest cost compo-
nent of diabetes management to the clinics. The cost of insulin
1000 I.U. to the clinics was GHS 19.25 (US $13.28) on average
depending on the type. Drug cost for the management of diabetes
complications was about twice the cost for the management of
diabetes (Fig. 2). The laboratory investigation cost was about 4%
and emergency services, hospitalization, and surgical costs
together accounted for about 3%. Those who were attended to
by a specialist (dietician, physician specialist, ophthalmologist, or
the surgeon) constituted 26%, and most of those who were
hospitalized stayed for longer periods, an average of 28.8 days.
The cost of hospitalization per patient-day at Cocoa clinics was
estimated at GHS 32.78 (US $22.61).
The cost of managing type 1 diabetes at Cocoa clinics is
almost twice the cost of managing type 2 diabetes (Table 2). An
independent t test of the means (P ¼ 0.001) indicated the
signiﬁcance of the type of diabetes mellitus in the ﬁnancial cost
of diabetes. The cost of managing diabetes mellitus with compli-
cations is more than twice the amount spent on managing
diabetes mellitus without complications (Table 2). This study
demonstrated that the type of facility (P ¼ 0.018), type of diabetes
(P ¼ 0.001), and presence or absence of diabetes complications (P
¼ 0.002) were signiﬁcant variables to the ﬁnancial cost of diabetes
to the clinics. The total ﬁnancial cost of diabetes management to
Cocoa clinics in 2009 was estimated at GHS 420,087.67 (US
$300,062.62). This constituted about 8% of the total expenditure
for the clinics.
90.87
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Fig. 1 – Comparison of the cost of diabetes at four Cocoa clinics. GHS, Ghana cedi.
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In determining the direct medical cost of diabetes, the quantities
and corresponding values of generic drugs, glibenclamide and
metformin, were extracted from the diabetic patients’ records
and used for the sensitivity analysis. The cost component for
each generic brand deducted from the mean ﬁnancial cost forTable 2 – Sociodemographic and clinical character-
istics correlated with ﬁnancial cost of managing
diabetes mellitus at Cocoa clinics.
Socio-demographic
Characteristicss
Financial cost
(GHS)*1 Mean  SD
P
-value
Facility type
Accra (n ¼ 184) 601.30  617.72 0.018
Kumasi (n ¼ 45) 450.84  360.07
Akim-Tafo (n ¼ 51) 368.46  215.59
Tema (n ¼ 24) 618.84  272.45
Age Group
o40 (n ¼ 11) 415.88  409.03 0.525
40–59 (n ¼ 198) 562.81  552.62
60þ (n ¼ 95) 511.15  462.12
Sex
Male (n ¼ 167) 581.69  535.73 0.134
Female (n ¼ 137) 492.17  500.10
Type of Client
Staff (n ¼ 138) 597.43  608.30 0.546
Dependent (n ¼ 54) 473.30  341.88
Retired Staff (n ¼ 82) 507.07  583.15
Insured (n ¼ 21) 478.77  491.36
Private (n ¼ 9) 506.07  583.15
Clinical state of diabetes patient
Type of diabetes
Type 1 (n ¼ 29) 906.74  591.90 0.001
Type 2 (n ¼ 275) 502.82  498.79
Complications
No complication (n ¼ 30) 262.18  152.86 0.002
ZOne complication (n ¼
274)
571.91  537.90
GHS, Ghana cedi.
* The 2009 exchange rate of US $1.00 was equivalent to GHS 1.45.diabetes revealed a reduction of 4.4% for metformin and 1.6% for
glibenclamide. The cost component for each of the corresponding
ethical brands added to the mean ﬁnancial cost also revealed an
increase of 69.4% for metformin and 19.7% for glibenclamide.Discussion
The management of diabetes is expensive, and the cost affects
individuals, families, society, health care providers, and national
productivity. This study provides a provider perspective of the
cost of managing diabetes. The public health implication of the
study is to provide cost-of-illness information for determining
the burden of disease and identifying areas for future interven-
tion by policymakers using the cost-of-illness approach. Efforts
were made in this study to include the relevant cost components
related to managing diabetes mellitus.
The clinical state of the diabetic patient had an inﬂuence on
the mean ﬁnancial cost of managing diabetes. Epidemiological
data suggest that in most populations at least 50%, and in
Tanzania 80% to 90%, of the people with diabetes have not been
diagnosed [17]. In Ghana, it has been reported that 69.9% cases of
diabetes are undiagnosed as a result of lack of diabetes aware-
ness and thus present late with complications [18]. This has
signiﬁcant cost implications. More than 90% of the patients with
diabetes had one or more complications.An-diabec drugs
24%
Complicaon drugs
47%
Lab invesgaons
4%
Other costs
3%
Service cost
22%
Fig. 2 – Cost components of diabetes management to Cocoa
clinics.
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was more than twice the cost of managing diabetes without
complications. Also, treatment of the complications required
regular monitoring of some indicators, for example, lipid proﬁle
for hyperlipidaemia. The complications also require specialist
care and sometimes hospitalization, which were predictor vari-
ables in the cost model. The delay in detecting and diagnosing
diabetes invariably increases costs of managing diabetes because
this causes them to come with complications.
The ﬁnancial cost of managing type 1 diabetes was about
twice the cost of managing type 2 diabetes. The mainstay
antidiabetic drug used for type 1 diabetes per the clinics’ guide-
lines is insulin. Regular insulin, NPH insulin, and the 30/70
mixture of regular and NPH were the three main types of insulin
on the clinics’ formulary at the time of the study. It was observed
that some diabetic patients require two or three vials of 1000 I.U.
of insulin in a month for managing the diabetes; because insulin
is expensive, it adds to the total cost of managing the disease. A
study on the diabetes cost model for Thailand reported a similar
trend. In the study by Riewpaiboon et al. [1], they estimated the
cost for type 1 diabetes without complications at US $502.96
whereas the cost of type 2 diabetes without complications was US
$190.07 [1].
However, the ﬁnancial cost varied for each facility. The
variation in the service cost was attributed to the fact that in
Tema most diabetic patients attended the facility on a monthly
basis, whereas in Accra most attended the facility every 3 to 4
months. Diabetes being a chronic disease requires regular
checkup; however, visits to the clinics for diabetes care depend
on the effectiveness of the management protocol followed for
each patient. Those whose blood sugar levels are well controlled
and who are adhering to treatment can visit the facility
bimonthly to reduce the service cost component of the ﬁnancial
cost of diabetes. This contributed to the low mean service cost for
diabetic patients in Accra. The direct medical cost was almost
twice in Accra compared with that in the other three facilities
because of the special services available (theater, ward, and
specialist care) at the facility.
The largest component of ﬁnancial cost was accounted for by
medicines. Most of the medicines were generic brands, which
were relatively cheaper. In our study, the total ﬁnancial cost of
managing diabetes mellitus for Cocoa clinics constituted 8% of
the total expenditure, which appears to be high for the 3% of the
clients suffering from diabetes, compared with 6% in the study on
direct medical costs for patients with type 2 diabetes in Sweden, a
developed country with a diabetic population of 3.5% [19].
The results of the sensitivity analysis indicated considerable
changes, with a unit change in the drug cost conﬁrming the
appropriateness of the parameters selected.
The study did not consider the duration of diabetes and which
comorbid condition was ﬁrst. In estimating the ﬁnancial cost of
diabetes management, the ﬁxed cost was not used and these
have been considered as limitations for this study.Conclusions
Determining the ﬁnancial cost of diabetes in this study showed
useful information relating to the high cost of managing diabetes
and the associated complications. The mean age suggests delay
in diagnosing diabetes and accompanying complications, which
has cost implications. A policy that enhances early detection of
diabetes in clinical practice would therefore improve manage-
ment and reduce costs. The ﬁnancial cost of managing diabetes
can be used to forecast the economic burden of the disease in
the area.There will be a need for the costing of other diseases using the
institutional/health care provider perspective. This will provide a
basis for comparing the results for policy advocacy. There is also
an urgent need for a health policy shift toward prevention and
effective control of diabetes through regular screening programs
in clinical practice for early detection and treatment. Finally, an
economic evaluation study on the prevention of diabetes is
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